These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9715839)

  • 1. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262).
    McCance-Katz EF; Rainey PM; Jatlow P; Friedland G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):435-43. PubMed ID: 9715839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of opioid dependence pharmacotherapies on zidovudine disposition.
    McCance-Katz EF; Rainey PM; Friedland G; Kosten TR; Jatlow P
    Am J Addict; 2001; 10(4):296-307. PubMed ID: 11783744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection.
    Schwartz EL; Brechbühl AB; Kahl P; Miller MA; Selwyn PA; Friedland GH
    J Acquir Immune Defic Syndr (1988); 1992; 5(6):619-26. PubMed ID: 1588496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
    Moore KH; Raasch RH; Brouwer KL; Opheim K; Cheeseman SH; Eyster E; Lemon SM; van der Horst CM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2732-7. PubMed ID: 8593010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.
    Morse GD; Portmore AC; Marder V; Plank C; Olson J; Taylor C; Bonnez W; Reichman RC
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2245-52. PubMed ID: 1444306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.
    Mirochnick M; Rodman JH; Robbins BL; Fridland A; Gandía J; Hitti J; Bardeguez A; Rathore MH; Gonzalez Garcia A; Cababasay M; Samson P; Mofenson L; Bryson YJ; Dorenbaum A
    HIV Med; 2007 Oct; 8(7):451-6. PubMed ID: 17760737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.
    Capparelli EV; Englund JA; Connor JD; Spector SA; McKinney RE; Palumbo P; Baker CJ
    J Clin Pharmacol; 2003 Feb; 43(2):133-40. PubMed ID: 12616665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease.
    Bareggi SR; Cinque P; Mazzei M; D'Arminio A; Ruggieri A; Pirola R; Nicolin A; Lazzarin A
    J Clin Pharmacol; 1994 Jul; 34(7):782-6. PubMed ID: 7929874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
    Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
    AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
    Burger DM; Meenhorst PL; ten Napel CH; Mulder JW; Neef C; Koks CH; Bult A; Beijnen JH
    AIDS; 1994 Dec; 8(12):1683-9. PubMed ID: 7888117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.
    Rolinski B; Bogner JR; Sadri I; Wintergerst U; Goebel FD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jul; 15(3):192-7. PubMed ID: 9257653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
    Brockmeyer NH; Tillmann I; Mertins L; Barthel B; Goos M
    Eur J Med Res; 1997 Sep; 2(9):377-83. PubMed ID: 9300934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the kinetics of zidovudine in the pregnant baboon following oral administration.
    Garland M; Szeto HH; Daniel SS; Tropper PJ; Myers MM; Stark RI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):433-40. PubMed ID: 9859956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.
    Hurwitz SJ; Asif G; Fromentin E; Tharnish PM; Schinazi RF
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1248-55. PubMed ID: 20038617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
    Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
    HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.